All In Biotech

Investigational drug · Phase 3

Fenebrutinib

Also called: RO7010939, GDC-0853, G02599853

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

18

Any phase or sponsor naming "Fenebrutinib"

First trial start

2020

Oct 26, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Fenebrutinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsing Multiple Sclerosis
  • Multiple Sclerosis
  • Multiple Sclerosis, Primary Progressive

Approved drugs for the same conditions: Multiple sclerosis · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Fenebrutinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 73 on PubMed

Also in development for Relapsing Multiple Sclerosis

  • PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease

  • ObexelimabPhase 34 trials

    Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis

  • TolebrutinibSAR442168Phase 33 trials

    Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

  • rapcabtagene autoleucelYTB323Phase 28 trials

    Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.